A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-17

Study Completion Date

2030-08-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept proposed in 2020. Unlike non-alcoholic fatter liver disease (NAFLD), the diagnosis of MAFLD requires the presence any of the following 3 metabolic risks, including overweight/obesity, presence of diabetes mellitus, and evidence of metabolic dysregulation. However, there are patients that have hepatic steatosis but no metabolic risk, who thus do not meet the diagnostic criteria of MAFLD. Besides, there are patients with both MAFLD and other liver diseases. The clinical features and the management of these patients remain unclear. Thus, further histopathological and clinical study is required to elucidate and compare the characteristics of MAFLD and NAFLD.

Here, in this single-center, prospective clinical study, investigators are planning to establish a long-term follow-up cohort of patients with either MAFLD or NAFLD. In order to understand the risk of developing liver-related complications and important extra-hepatic outcomes (e.g. cardiovascular disease), and also to better elucidate the risk of disease progression in "lean" NAFLD individuals without any metabolic dysregulation and MAFLD individuals with dual or multiple causes.

Ultimately, investigators aim to improve the diagnosis of MAFLD and improve patients' outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Characteristics of Metabolic Associated Fatty Liver Disease

NCT06325254

Metabolic Associated Fatty Liver Disease Clinical Features

RECRUITING

MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

NCT04761900

Metabolic Associated Fatty Liver Disease

COMPLETED

Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

NCT05421572

Fatty Liver Disease

UNKNOWN

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study

NCT03534908

NAFLD Cardiovascular Diseases

UNKNOWN

Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

NCT02285218

Non-alcoholic Fatty Liver Disease Type 2 Diabetes Metabolic Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is divided into 2 parts:

Firstly, it contains a cross-sectional study to collect the clinical data of the patients with fatty liver. The clinical features of this population will be analysed.

Secondly, the study will collect the plasma, urine and stool samples of the patients in this cohort. And then a long-term follow-up of these patients will be carried out. Investigators wish to find out biomarkers that can detail patient stratification and predict the prognosis of the disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Associated Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed as hepatic steatosis in adults (fulfill at least one of the followings):

1. Liver ultrasound shows liver parenchymal hyperechoic or "bright liver"
2. Controlled attenuation-parameter (CAP) ≥248dB/m
3. Hepatic steatosis diagnosed by CT/MRI/MRS
4. MRI-based proton-density fat fraction (MRI-PDFF) shows liver fat content\>8%
5. Fatty liver confirmed by liver histology.

Exclusion Criteria

1. Diagnosed with hepatocellular carcinoma or other malignancy (in accordance with the appropriate diagnostic criteria);
2. During pregnancy;
3. Patients with history of liver transplantation;
4. Patients with serious cardiovascular and cerebrovascular events (such as acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No